<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00227669</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000443572</org_study_id>
    <secondary_id>FRE-FNCLCC-SARCOME-07/0410</secondary_id>
    <secondary_id>EU-20518</secondary_id>
    <nct_id>NCT00227669</nct_id>
  </id_info>
  <brief_title>Gemcitabine With or Without Docetaxel as Second-Line Therapy in Treating Patients With Metastatic or Relapsed, Unresectable Uterine or Soft Tissue Leiomyosarcoma</brief_title>
  <official_title>Randomized Phase II Study Evaluating the Efficacy of Gemcitabine Versus the Gemcitabine/Docetaxel Combination as Second Line Treatment in Metastatic or Relapsed and Inoperable Uterine or Soft Tissue Leiomyosarcomas</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>UNICANCER</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>UNICANCER</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy, such as gemcitabine and docetaxel, work in different&#xD;
      ways to stop the growth of tumor cells, either by killing the cells or by stopping them from&#xD;
      dividing. Giving more than one drug (combination chemotherapy) may kill more tumor cells. It&#xD;
      is not yet known whether giving gemcitabine together with docetaxel is more effective than&#xD;
      giving gemcitabine alone as second-line therapy in treating uterine or soft tissue&#xD;
      leiomyosarcoma.&#xD;
&#xD;
      PURPOSE: This randomized phase II trial is studying gemcitabine and docetaxel to see how well&#xD;
      they work compared to gemcitabine alone as second-line therapy in treating patients with&#xD;
      metastatic or relapsed, unresectable uterine or soft tissue leiomyosarcoma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  Compare the anti-tumor activity, in terms of objective response rate, in patients with&#xD;
           metastatic or relapsed, unresectable uterine or soft tissue leiomyosarcoma treated with&#xD;
           gemcitabine with vs without docetaxel as second-line therapy.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  Compare the progression-free survival of patients treated with these regimens.&#xD;
&#xD;
        -  Compare the response duration and overall survival of patients treated with these&#xD;
           regimens.&#xD;
&#xD;
        -  Compare the tolerability and dose intensity of these regimens in these patients.&#xD;
&#xD;
        -  Determine biological markers with a predictive value for response to these regimens in&#xD;
           these patients.&#xD;
&#xD;
      OUTLINE: This is a randomized study. Patients are stratified according to location of&#xD;
      leiomyosarcoma (uterine vs soft tissue). Patients are randomized to 1 of 2 treatment arms.&#xD;
&#xD;
        -  Arm I: Patients receive gemcitabine on days 1, 8, and 15. Treatment repeats every 4&#xD;
           weeks for 2-8 courses.&#xD;
&#xD;
        -  Arm II: Patients receive gemcitabine on days 1 and 8 and docetaxel on day 8. Treatment&#xD;
           repeats every 3 weeks for 2-8 courses.&#xD;
&#xD;
      PROJECTED ACCRUAL: A minimum of 80 patients (40 per stratum and treatment arm) will be&#xD;
      accrued for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2005</start_date>
  <completion_date type="Actual">August 2012</completion_date>
  <primary_completion_date type="Actual">February 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Anti-tumoral activity (objective response rate)</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response duration</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tolerability</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dose intensity</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biological markers</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">90</enrollment>
  <condition>Sarcoma</condition>
  <arm_group>
    <arm_group_label>Arm I: Gemcitabine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Gemcitabine at Day 1, Day 8 and Day 15. No treatment at Day 22.&#xD;
1 cycle = 28 days.&#xD;
Treatment duration: 8 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm II: Gemcitabine + Docetaxel</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Gemcitabine at Day 1 and Day 8. No treatment at Day 15. Docetaxel at Day 8.&#xD;
1 cycle = 21 days.&#xD;
Treatment duration: 6 months</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>docetaxel</intervention_name>
    <arm_group_label>Arm II: Gemcitabine + Docetaxel</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>gemcitabine hydrochloride</intervention_name>
    <arm_group_label>Arm I: Gemcitabine</arm_group_label>
    <arm_group_label>Arm II: Gemcitabine + Docetaxel</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed uterine or soft tissue leiomyosarcoma, meeting ≥ 1 of the&#xD;
             following criteria:&#xD;
&#xD;
               -  Metastatic disease&#xD;
&#xD;
               -  Relapsed and unresectable disease&#xD;
&#xD;
          -  Prior treatment with a first-line anthracycline-based chemotherapy regimen required&#xD;
&#xD;
               -  Relapsed disease &gt; 1 year after adjuvant chemotherapy is considered untreated&#xD;
                  disease&#xD;
&#xD;
               -  If relapsed disease occurs &lt; 1 year after adjuvant therapy, then adjuvant therapy&#xD;
                  is considered a first-line treatment&#xD;
&#xD;
          -  At least 1 measurable lesion, defined as the following:&#xD;
&#xD;
               -  At least 1 target lesion must be located in a non-irradiated area&#xD;
&#xD;
               -  Obvious disease progression within the past 6 weeks&#xD;
&#xD;
          -  No other uterine sarcomas, including any of the following:&#xD;
&#xD;
               -  Carcinosarcoma&#xD;
&#xD;
               -  Endometrial stroma sarcoma&#xD;
&#xD;
               -  Other soft tissue sarcoma&#xD;
&#xD;
          -  No symptomatic or known brain metastases&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age&#xD;
&#xD;
          -  18 and over&#xD;
&#xD;
        Performance status&#xD;
&#xD;
          -  WHO 0-2&#xD;
&#xD;
        Life expectancy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hematopoietic&#xD;
&#xD;
          -  Absolute neutrophil count ≥ 1,000/mm^3&#xD;
&#xD;
          -  Platelet count ≥ 100,000/mm^3&#xD;
&#xD;
        Hepatic&#xD;
&#xD;
          -  Bilirubin ≤ 1.5 times upper limit of normal (ULN)&#xD;
&#xD;
          -  AST and ALT ≤ 2.5 times ULN&#xD;
&#xD;
          -  Alkaline phosphatase ≤ 2.5 times ULN&#xD;
&#xD;
          -  No specific hepatic contraindication to study treatment&#xD;
&#xD;
          -  Hepatitis B core and hepatitis B surface antigen negative&#xD;
&#xD;
        Renal&#xD;
&#xD;
          -  Creatinine &lt; 1.5 times ULN&#xD;
&#xD;
          -  No specific renal contraindication to study treatment&#xD;
&#xD;
        Cardiovascular&#xD;
&#xD;
          -  No specific cardiac contraindication to study treatment&#xD;
&#xD;
        Immunologic&#xD;
&#xD;
          -  HIV negative&#xD;
&#xD;
          -  No specific allergic contraindication to study treatment&#xD;
&#xD;
          -  No active infection&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  No other serious underlying pathology that would preclude study treatment&#xD;
&#xD;
          -  No other prior malignancy except basal cell skin cancer or carcinoma in situ of the&#xD;
             cervix&#xD;
&#xD;
          -  No neurotoxicity &gt; grade 2&#xD;
&#xD;
          -  No psychological, sociological, or geographical condition that would preclude study&#xD;
             compliance or follow-up schedule&#xD;
&#xD;
          -  No prior or concurrent psychiatric illness&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy&#xD;
&#xD;
          -  More than 4 weeks since prior immunotherapy&#xD;
&#xD;
          -  No prior allogeneic graft or autologous graft&#xD;
&#xD;
        Chemotherapy&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  More than 4 weeks since prior chemotherapy&#xD;
&#xD;
          -  No prior gemcitabine and/or taxane (i.e., docetaxel or paclitaxel)&#xD;
&#xD;
        Endocrine therapy&#xD;
&#xD;
          -  More than 4 weeks since prior hormonal therapy&#xD;
&#xD;
        Radiotherapy&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  More than 4 weeks since prior radiotherapy&#xD;
&#xD;
          -  No prior radiotherapy to the only evaluable lesion&#xD;
&#xD;
        Surgery&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  No concurrent participation in another clinical trial using an experimental agent&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>120 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Florence Duffaud, MD</last_name>
    <role>Study Chair</role>
    <affiliation>CHU de la Timone</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire d'Amiens</name>
      <address>
        <city>Amiens</city>
        <zip>80054</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Paul Papin</name>
      <address>
        <city>Angers</city>
        <zip>49036</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>C.H.G. Beauvais</name>
      <address>
        <city>Beauvais</city>
        <zip>60021</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Bergonie</name>
      <address>
        <city>Bordeaux</city>
        <zip>33076</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>C.H.U. de Brest</name>
      <address>
        <city>Brest</city>
        <zip>29609</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Regional Francois Baclesse</name>
      <address>
        <city>Caen</city>
        <zip>14076</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Jean Perrin</name>
      <address>
        <city>Clermont-Ferrand</city>
        <zip>63011</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Louis Pasteur</name>
      <address>
        <city>Colmar</city>
        <zip>68024</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre de Lutte Contre le Cancer Georges-Francois Leclerc</name>
      <address>
        <city>Dijon</city>
        <zip>21079</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Oscar Lambret</name>
      <address>
        <city>Lille</city>
        <zip>59020</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Leon Berard</name>
      <address>
        <city>Lyon</city>
        <zip>69373</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Edouard Herriot - Lyon</name>
      <address>
        <city>Lyon</city>
        <zip>69437</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de la Timone</name>
      <address>
        <city>Marseille</city>
        <zip>13385</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Nord</name>
      <address>
        <city>Marseille</city>
        <zip>13915</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Regional de Lutte Contre le Cancer - Centre Val d'Aurelle</name>
      <address>
        <city>Montpellier</city>
        <zip>34298</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Regional Rene Gauducheau</name>
      <address>
        <city>Nantes-Saint Herblain</city>
        <zip>44805</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHR Hotel Dieu</name>
      <address>
        <city>Nantes</city>
        <zip>44093</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Antoine Lacassagne</name>
      <address>
        <city>Nice</city>
        <zip>06189</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHR D'Orleans - Hopital de la Source</name>
      <address>
        <city>Orleans</city>
        <zip>45067</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Bichat - Claude Bernard</name>
      <address>
        <city>Paris</city>
        <zip>75018</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Curie Hopital</name>
      <address>
        <city>Paris</city>
        <zip>75248</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Saint-Louis</name>
      <address>
        <city>Paris</city>
        <zip>75475</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Cochin</name>
      <address>
        <city>Paris</city>
        <zip>75674</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Poitiers</name>
      <address>
        <city>Poitiers</city>
        <zip>86021</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Eugene Marquis</name>
      <address>
        <city>Rennes</city>
        <zip>35042</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Charles Nicolle</name>
      <address>
        <city>Rouen</city>
        <zip>76031</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Henri Becquerel</name>
      <address>
        <city>Rouen</city>
        <zip>76038</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Rene Huguenin</name>
      <address>
        <city>Saint Cloud</city>
        <zip>92211</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut de Cancerologie de la Loire</name>
      <address>
        <city>Saint Priest en Jarez</city>
        <zip>42270</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Claudius Regaud</name>
      <address>
        <city>Toulouse</city>
        <zip>31052</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire Bretonneau de Tours</name>
      <address>
        <city>Tours</city>
        <zip>37044</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Gustave Roussy</name>
      <address>
        <city>Villejuif</city>
        <zip>F-94805</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <results_reference>
    <citation>Duffaud F, Bui BN, Penel N, et al.: A FNCLCC French Sarcoma Group--GETO multicenter randomized phase II study of gemcitabine (G) versus gemcitabine and docetaxel (G+D) in patients with metastatic or relapsed leiomyosarcoma (LMS). [Abstract] J Clin Oncol 26 (Suppl 15): A-10511, 2008.</citation>
  </results_reference>
  <verification_date>August 2016</verification_date>
  <study_first_submitted>September 26, 2005</study_first_submitted>
  <study_first_submitted_qc>September 26, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 28, 2005</study_first_posted>
  <last_update_submitted>August 29, 2016</last_update_submitted>
  <last_update_submitted_qc>August 29, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 30, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>uterine leiomyosarcoma</keyword>
  <keyword>stage III adult soft tissue sarcoma</keyword>
  <keyword>stage IV adult soft tissue sarcoma</keyword>
  <keyword>recurrent adult soft tissue sarcoma</keyword>
  <keyword>stage III uterine sarcoma</keyword>
  <keyword>stage IV uterine sarcoma</keyword>
  <keyword>recurrent uterine sarcoma</keyword>
  <keyword>adult leiomyosarcoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sarcoma</mesh_term>
    <mesh_term>Leiomyosarcoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Docetaxel</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Individual participant data will not be shared at an individual level.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

